ADVFN - Advanced Financial Network.
HOME» NYSE » M » MRK Stock Price » MRK Stock News

Merck Share News

 Merck & Co., Stock Price
MRK Stock Price
 Merck & Co., Stock Chart
MRK Stock Chart
 Merck & Co., Stock News
MRK Stock News
 Merck & Co., Company Information
MRK Company Information
 Merck & Co., Stock Trades
MRK Stock Trades

Cardiome To Slash Workforce by 85% on End of Merck's Oral Development Program

By Chelsea Stevenson Cardiome Pharma Corp. (CRME) plans to reduce its workforce by about 85% in response to the termination of Merck & Co.'s (MRK) developing vernakalant oral program. All positions focused on internal research and certain supporting functions will be eliminated, Canadian-based Cardiome Pharma said. The reductions will result in up to $5 million in severance charges over the remainder of the year. In March, Cardiome's partner Merck discontinued its development of its oral vernakalant drug, which prevented atrial fibrillation. Cardiome had said it was disappointed with Merck's decision. Interim Chief Executive Dr. William Hunter said the board regrets the effects of the decision. Dr. Hunter replaced former Chief Executive Doug Janzen, who left the company last week. Cardiome Pharma reported a slightly narrower loss for its first quarter, citing clinical development efforts and pre-clinical research project expenditures. The latest quarter's loss also includes employee termination charges. The company said it will issue a further progress report in mid-August to its shareholders. Shares were off 2.3% to 43 cents in recent trading and have dropped 84% this year. Write to Chelsea Stevenson at chelsea.stevenson@dowjones.com

Stock News for Merck (MRK)
DateTimeHeadline
08/23/201603:03:00Deal for Medivation Is the Latest In a Line of Similar Acquisitions...
08/22/201612:52:00Pfizer's Medivation Deal Latest in Long Line of Similar Acquisitions
08/10/201616:58:47Statement of Changes in Beneficial Ownership (4)
08/09/201603:03:00Botox Maker Allergan's Revenue Climbs, but Loss More Than Doubles...
08/08/201617:05:00Results from Merck’s Phase 3 Study Evaluating ZEPATIER™ (elbasvir & g...
08/08/201616:41:16Quarterly Report (10-q)
08/08/201614:56:00Allergan Revenue Increases, Though Loss Widens--Update
08/08/201611:59:00MARKET SNAPSHOT: Stocks Retreat From Records As Health-care Stocks...
08/08/201610:20:00MARKET SNAPSHOT: Stocks Fight To Maintain Record-setting Pace...
08/08/201606:45:00REPEAT/FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Pa...
08/05/201619:30:00FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Patients wi...
08/05/201617:49:32Statement of Changes in Beneficial Ownership (4)
08/05/201612:58:00Bristol Myers: Opdivo Failed to Meet Endpoint in Key Lung Cancer...
08/05/201610:36:00Bristol Myers: Opdivo Failed to Meet Endpoint in Key Lung Cancer...
08/05/201610:15:00Bristol Myers: Opdivo Failed to Meet Endpoint in Key Lung Cancer...
08/05/201609:39:00Bristol Myers: Opdivo Failed to Meet Endpoint in Key Lung Cancer...
08/05/201609:20:00Bristol Myers: Opdivo Failed to Meet Endpoint in Key Lung Cancer...
08/05/201609:12:00Bristol Myers: Opdivo Failed to Meet Endpoint in Key Lung Cancer...
08/05/201608:00:00Merck Announces U.S. FDA Filing Acceptance of New Drug Application...
08/04/201614:30:37Statement of Changes in Beneficial Ownership (4)

Merck and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2015 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad